TCT-517 Long term clinical outcome following Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-stent Restenosis: a Multicenter Italian Experience

In this contest the use of bioresorbable vascular scaffold (BVS) appears very attractive as it allows drug delivery combined with transient vessel scaffolding thus obviating the limitations of drug-eluting stent or balloon as ISR therapy. Primary endpoints were procedural success defined as the succ...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2015-10, Vol.66 (15), p.B211-B211
Main Authors: Moscarella, Elisabetta, Varricchio, Attilio, Granata, Francesco, Coscarelli, Sebastian, Stabile, Eugenio, Latib, Azeem, Ielasi, Alfonso, Cortese, Bernardo, Tespili, Maurizio, Calabrò, Paolo, Tanaka, Akihito, Capozzolo, Claudia, Colombo, Antonio
Format: Article
Language:English
Subjects:
Angioplasty
Cardiology
Cardiovascular
Heart attacks
Internal Medicine
Stents
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this contest the use of bioresorbable vascular scaffold (BVS) appears very attractive as it allows drug delivery combined with transient vessel scaffolding thus obviating the limitations of drug-eluting stent or balloon as ISR therapy. Primary endpoints were procedural success defined as the successful delivery and deployment of the BVS at the target lesion with less than 30% final residual stenosis without in-hospital major adverse cardiac and/or cerebro-vascular events (MACCE) defined as a composite of cardiac death, Q-wave myocardial infarction, stroke, or any repeat target lesion revascularization (surgical or percutaneous).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2015.08.534